Cabaletta Bio, Inc. announced promising results from its ongoing RESET clinical trials for its investigational therapy rese-cel, focusing on autoimmune diseases. In the trials, notable outcomes ...

• In the Phase 1 portion of the CELC-G-201 clinical trial evaluating gedatolisib plusdarolutamide in men with metastatic castration resistant prostate cancer (“mCRPC”),the six-month radiographic ...

Extended half-life and local bioactivation support convenient once-daily dosing in ulcerative colitis (UC) and fibrostenotic Crohn’s disease (FSCD) Colon tissue drug levels exceeded target thresholds ...

8 of 9 participants (89%) treated in the 240mg and 360mg single dose cohorts achieved a complete response 8 of 11 participants (73%) enrolled in the 180mg Q8W open label extension study achieved a ...

As the clock ticks closer to the new year, DrBicuspid thought it was time to revisit some of the most intriguing and popular case reports published in 2025. This year’s top stories included patient ...